Stock Events

Stock Events

Cingulate 

$6.75
0
+$0.47+7.48% Monday 07:35

Statistics

Day High
6.75
Day Low
6.39
52W High
-
52W Low
-
Volume
2,753
Avg. Volume
-
Mkt Cap
45.61M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2025
Q4 2025
Next
-1.35
-1.06
-0.77
-0.48
Expected EPS
-0.48
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-31.09MNet Income

Analyst Ratings

$36.00Average Price Target
The highest estimate is 58.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CING.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Supernus Pharmaceuticals
SUPN
Mkt Cap3.12B
Supernus Pharmaceuticals has a portfolio including ADHD treatments, competing in the same market as Cingulate.
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
Takeda Pharmaceutical Company offers a range of ADHD medications, making it a direct competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, offers ADHD medications, competing in the same therapeutic area.
Novartis
NVS
Mkt Cap237.61B
Novartis AG provides medications for ADHD, making it a competitor in the same treatment category.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has a diverse portfolio that includes treatments for neurological disorders, potentially competing in the ADHD space.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly and Company has been involved in psychiatric and neurological treatments, potentially competing with Cingulate's ADHD focus.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries has a broad portfolio that includes CNS treatments, indirectly competing with Cingulate.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. focuses on innovative therapies, including for neurological conditions, potentially putting it in competition with Cingulate.

About

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Show more...
CEO
ISIN
US17248W3034

Listings

XNAS
US
CING
XNAS
US
CINGW
BOATS
BOATS
CING.BOATS

0 Comments

Share your thoughts

FAQ

What is Cingulate stock price today?▼
The current price of CING.BOATS is $6.75 USD — it has increased by +7.48% in the past 24 hours. Watch Cingulate stock price performance more closely on the chart.
What is Cingulate stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cingulate stocks are traded under the ticker CING.BOATS.
What is Cingulate market cap?▼
Today Cingulate has the market capitalization of 45.61M
When is the next Cingulate earnings date?▼
Cingulate is going to release the next earnings report on May 13, 2026.
What were Cingulate earnings last quarter?▼
CING.BOATS earnings for the last quarter are -0.96 USD per share, whereas the estimation was -0.63 USD resulting in a -51.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cingulate revenue for the last year?▼
Cingulate revenue for the last year amounts to 0 USD.
What is Cingulate net income for the last year?▼
CING.BOATS net income for the last year is -31.09M USD.
When did Cingulate complete a stock split?▼
Cingulate has not had any recent stock splits.